Harnessing the power of the gut microbiome in colorectal cancer
Lessons learned about the importance of the gut microbiome composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care
Lessons learned about the importance of the gut microbiome composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care
In the TRANSMET trial, a 5-year overall survival benefit was observed in a highly selected patient population
Final results of the KEYNOTE-585 study indicate that the current treatment standard for resectable G/GEJ should remain unchanged
Recent data indicate a role of immunotherapy for tumours with high levels of microsatellite instability, especially in the neoadjuvant setting
Innovative approaches are investigated to predict cancer development in patients with cirrhosis and detect early recurrence after resection
Promising data from a subgroup analysis of the phase III NETTER-2 study support the use of peptide receptor radionuclide therapy in treatment-naïve patients
The development of KRAS selective inhibitors promises to expand treatment to a broader population of patients with KRAS-mutated tumours
Research is moving forward to adapt clinical practice to a new wave of early-onset cases of cancer in the digestive tract
Recent data from studies show novel pre-operative therapeutic options, but many pending issues need to be addressed
Improvements in the understanding of molecular mechanisms, together with a greater focus on prevention, are key elements to countering gynaecological malignancies
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.